ACE inhibition by fosinopril did not have a beneficial effect on quadriceps muscle function over a 3-month period in patients with COPD selected for quadriceps weakness, although measurements of BP and serum ACE activity confirmed both adherence and biologic activity of the drug. The gene discussed is ACE; the disease is chronic obstructive pulmonary disease.